Halozyme’s PEGPH20 pancreas cancer drug candidate fails in HALO-301 trial

This article was originally published here

PEGPH20 was being assessed in combination with ABRAXANE (nab-paclitaxel) and gemcitabinein in the HALO-301 study as a first-line therapy for the condition. The late-stage trial enrolled 500 patients

The post Halozyme’s PEGPH20 pancreas cancer drug candidate fails in HALO-301 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply